Delivery Order 36C25725D0021-36C25725N0176

Award Date 1/28/25
Potential Completion Date 1/26/26
Potential Value $1.9M
Ultimate Awardee
Cardinal Health, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Dublin, OH 43017, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $347,981.58, was issued by the Veterans Integrated Service Network 19 (VISN 19) of the U.S. Department of Veterans Affairs (VA) to Cardinal Health 414, LLC, a subsidiary of Cardinal Health, Inc. The contract is for the delivery of radiopharmaceuticals, including technetium-99m, iodine-123, iodine-131, indium-111, thallium-201, fluorine-18 FDG, and gallium-67, as well as radiopharmaceutical therapies such as Xofigo (radium-223 dichloride) for prostate cancer...
This federal contract award, valued at $405,154.73, was issued by the Department of Veterans Affairs (VA) to Cardinal Health 414, LLC, a subsidiary of Cardinal Health, Inc. The contract is for the delivery of radiopharmaceuticals, including technetium-99m, iodine-123, iodine-131, indium-111, thallium-201, fluorine-18 FDG, and gallium-67, as well as radiopharmaceutical therapies such as Xofigo (radium-223 dichloride) for prostate cancer treatment. These products are delivered to VA medical...
This is a firm-fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Cardinal Health 414, LLC, a subsidiary of the global healthcare company Cardinal Health, Inc. The contract is for the delivery of radiopharmaceuticals, including technetium-99m, iodine-123, iodine-131, indium-111, thallium-201, fluorine-18 FDG, and gallium-67, as well as radiopharmaceutical therapies like Xofigo, to support nuclear medicine, oncology, and...
This federal contract award, valued at $801,456.68, was issued by the Veterans Integrated Service Network 21 (VISN 21) to Cardinal Health 414, LLC, a subsidiary of Cardinal Health, Inc. The contract is for the provision of radiopharmaceuticals, including technetium-99m, iodine-123, iodine-131, indium-111, thallium-201, fluorine-18 FDG, and gallium-67, as well as radiopharmaceutical therapies like Xofigo (radium-223 dichloride) for prostate cancer treatment. This delivery order contract has a...
This $80,260 firm fixed-price purchase order was awarded by the Department of Veterans Affairs (VA) to Cardinal Health 414, LLC, a subsidiary of Cardinal Health, Inc. The contract is for the provision of radiopharmaceuticals, including technetium-99m, iodine-123, iodine-131, indium-111, thallium-201, fluorine-18 FDG, and gallium-67, as well as radiopharmaceutical therapies like Xofigo (radium-223 dichloride) for prostate cancer treatment. This contract is not set aside for any specific...
This federal contract award is for the delivery of radiopharmaceuticals to the Veterans Integrated Service Network 8 (VISN 8), a healthcare system operated by the U.S. Department of Veterans Affairs (VA). The prime contractor is Cardinal Health 414, LLC, a subsidiary of Cardinal Health, Inc. that specializes in providing nuclear medicine products and services to federal agencies. The $1,665,909.11 contract is a delivery order under an Indefinite Delivery Vehicle (IDV) held by Cardinal Health 414...
This federal contract award is for the delivery of radiopharmaceuticals to the U.S. Department of Veterans Affairs (VA). The prime contractor is Cardinal Health 414, LLC, a subsidiary of the global healthcare services company Cardinal Health, Inc. The contract has an award value of $143,657.73 and a period of performance through September 29, 2024. The contract is a delivery order under an Indefinite Delivery Vehicle (IDV), which allows the VA to order a range of radiopharmaceutical products,...
This federal contract award was issued by the Veterans Integrated Service Network 23 of the U.S. Department of Veterans Affairs (VA) to Cardinal Health 414, LLC, a subsidiary of Cardinal Health, Inc. The $181,474.01 firm fixed-price delivery order contract is for the supply of radiopharmaceuticals, which are specialized pharmaceutical products used in nuclear medicine, oncology, and diagnostic imaging services. The contract is not set aside for any specific business type. Cardinal Health 414 has...
This is a federal contract award from the Department of Veterans Affairs (VA) to Cardinal Health, Inc., a global healthcare services and products company. The contract is for the delivery of radiopharmaceuticals for use in nuclear medicine procedures within the VA healthcare system. The contract has a firm fixed-price delivery order valued at $983,677.24 covering the period from January 18, 2022, to January 18, 2023. This is part of a larger indefinite delivery contract (IDC) valued at...
This is a firm-fixed-price delivery order contract awarded to Cardinal Health 414, LLC, a subsidiary of Cardinal Health, Inc., to provide radiopharmaceuticals to the Department of Veterans Affairs (VA) Veterans Health Administration Veterans Integrated Service Network 21. The contract has a potential value of $406,942.11 and covers the delivery of various radiopharmaceuticals, including technetium-99m, iodine-123, iodine-131, indium-111, thallium-201, fluorine-18 FDG, and gallium-67, as well...
  • 36C25725D0021
    Indefinite Delivery Contract
  • 36C25725D0021-36C25725N0176
    Delivery Order

This is a federal contract award to Cardinal Health 414, LLC, a subsidiary of Cardinal Health, Inc., to provide radiopharmaceuticals to the Department of Veterans Affairs (VA). The contract, valued at $1,850,745.85, is a delivery order under a larger indefinite delivery vehicle (IDV) contract with the VA's Veterans Integrated Service Network 17. The contract covers the supply of various radiopharmaceuticals, including technetium-99m, iodine-123, iodine-131, indium-111, thallium-201, fluorine-18 FDG, and gallium-67, as well as radiopharmaceutical therapies like Xofigo (radium-223 dichloride) for prostate cancer treatment. This contract supports nuclear medicine programs at VA medical facilities through both routine and emergency deliveries. The contract is a firm fixed-price arrangement with a performance period through January 26, 2026 and does not have a set-aside designation.

Generated 1/29/25, 9:15 AM